New anti-diabetic agents
Journal of the Korean Medical Association
;
: 992-997, 2017.
Article
in Korean
| WPRIM
| ID: wpr-158094
ABSTRACT
Diabetes mellitus is characterized by hyperglycemia due to insulin deficiency and/or insulin resistance. Cardiovascular disease (CVD) is a major comorbidity of type 2 diabetes mellitus, and is the most common cause of death in people with diabetes mellitus. Several clinical trials have addressed the long-term effects of near-normoglycemia on CVD, but did not find evidence of an effect. However, some recent clinical trials of sodium glucose cotransporter 2 inhibitors (EMPA-REG [Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes Trial], CANVAS [Canagliflozin Cardiovascular Assessment Study]) or glucagon-like peptide-1 agonists (LEADER [Liraglutide Effect and Action in Diabetes Evaluation of Cardiovascular Outcome Results-A Long Term Evaluation], SUSTAIN-6 [Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes]) showed very promising results regarding the prevention of CVD. In this review, I discuss some of these new anti-diabetic agents and present clinical information regarding these drugs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Sodium
/
Insulin Resistance
/
Cardiovascular Diseases
/
Comorbidity
/
Mortality
/
Cause of Death
/
Diabetes Mellitus
/
Diabetes Mellitus, Type 2
/
Glucagon-Like Peptide 1
/
Glucose
Type of study:
Prognostic study
Language:
Korean
Journal:
Journal of the Korean Medical Association
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS